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1 S125 I Strategies for prevention of CMV infection and 
disease in transplant recipients 
€? Ljungman. Dept. cf Hematdon, Huddinge University Hospital, 
Karolinska Institutet, Huddinge, Sweden 
The morbidity and mortality in CMV disease in solid organ and 
bone marrow transplant recipients have been reduced during the last 
decade. Several different advances in management have contributed 
to this development. In patients who are seronegative to CMV at 
the time of transplantation it is of major importance whenever pos- 
sible to prevent the transmission of CMV through se!ection of organ 
donors and the use of screened or leukocyte depleted blood prod- 
ucts. In patients who are seropositive at the time of transplantation 
or in whom a CMV negative organ is not available preventive strate- 
gies should be designed based on the risk group of the patients. In 
low risk organ transplant patients prophyhs is usually not neces- 
s a r y  but the patients should be followed with a sensitive diagnostic 
technique such as antigenemia of PCR and therapy initiated either 
on a preemptive basis or deferred dependmg on the &cal status 
of the patient. In intermediate risk patients either prophylaxis or 
an preemptive strategy could be considered while in high risk pa- 
tients antivid prophylaxis with ganciclovir has been shown to be 
effective. In bone marrow transplant patients the use of either antivi- 
ral prophylaxis or preemptive therapy based on sensitive diagnostic 
technique are essential to prevent the development of fiequently fa- 
tal CMV disease. Several merent recent developments today allow 
risk-adapted preventive strategies for prevention of CMV disease in 
transplant patients. 
Fungal infections in the solid organ transplant 
recipient 
I? Mufioz. Hospital General Universitario “Gregorio Maraibn”, Madrid, 
Spain 
Rejection and mfection are the commonest early complications of 
solid organ transplant recipients. Although viral and bacterial infec- 
tions are more ftequent, invasive fungal infections carry the highest 
morbidity and mortality rates. 
The main fungal pathogen, the c h c a l  presentation and the prog- 
nosis vary according to the type of allografc. Common risk factors 
are breakdown of cutaneous-mucosal integrity, immunosuppression, 
concurrent infections and CMV disease. 
Disseminated candidiasis and invasive pulmonary aspergdlosis are 
the most frequent mycoses that cause Me-threatening infection in 
these patients. Candida is common after procedures requiring ab- 
dominal surgery. Aspergillus predominates in heart and heart-lung re- 
cipients. Dimorphc fungi must be considered in endemic areas and 
new emerging fungal pathogens are being increasingly recognized. 
Early detection is often difficult, and an aggressive workup has to 
be performed in most instances to obtain the diagnosis antemortem. 
Amphotericin B has been the mainstay of treatment, but its use can 
be associated with significant toxicity in patients on cyclosporine. 
New drugs are avadable nowadays, although experience is s d  scarce. 
The role of antifungal prophylaxis is controversd. All these fields 
will be reviewed. 
I S127 I Cells and Cytokines in the Pathogenesis of 
Opportunistic Infections 
J.S. Remington. Stanford University, Palo Alto, C A ,  USA 
Despite remarkable advances in organ transplantation, infections due 
to opportunistic pathogens continue to cause sigmficant morbid- 
itylmortality in these patients. Cell mediated immunity and the 
lymphocyte-monocyte-macrophage arm of the immune system may 
be markedly suppressed in organ transplant recipients, primarily due 
to reaction against the allograft and the immunosuppressive drugs 
they are receiving. This problem has served as an impetus for studies 
on the immunopathogenesis of fungal, bacterial, viral and proto- 
zoan infections against whch cells and cytokines are the primary 
mechanisms of host defense. In addition to the cytotoxic potential of 
CD4+ and CD8’ T cells, Thl- and ThZcytokine expression pat- 
terns have been correlated with outcome of these mfections. Both 
immunopathology and pathogen growth is lneuenced by the bal- 
ance between these responses and resistance or susceptibility to these 
infections has been correlated with the antimicrobial Thl  and Th2 
responses respectively. Resistance against many intracellular organ- 
isms is associated with induction of a Thl  response and particu- 
larly with the macrophage-activating cytokines, IFN-y and TNF-a . 
A Thl response is also critical for most d infections although 
IFN-a/B- activated NK cells, cytolyac T lymphocytes and neutral- 
izing antibomes are also important for host resistance against viruses. 
Induction of IL-12 secretion during the early stages of many of these 
intracellular mfections is critical for initiation of IFN-y dependent 
resistance and development of a Thl response; it can also convert a 
Th2 response to a Thl  pattern. Many organisms are able to directly 
stimulate macrophages to produce IL-12 and TNF-a and thereby, 
along with IL-15, activate NK cells to produce IFN-y; this  occurs 
prior to the conventional T cell response and thereby provides one of 
the earliest (inate) responses against infectious agents. IL-12 admin- 
istered early in murine models of infection has provided protection 
against a variety of intracellular pathogens and has proved a valu- 
able adjuvant for vaccines. The role of the various cytokines, their 
cross-regulation, and their potential for treating infectious diseases 
wdl be dwussed. 
I S128 I The Indirect Effects of Infection on H o s t  
R.H. Harvard. M I T  Division cfHealth .%ewes and Ethnology, 
Cambridge, MA, USA 
Cytokines and growth factors liberated in the course of infection 
can influence the occurrence of other mfecnons, modulate the re- 
currence of allograft injury, and play a role in the process of onco- 
genesis. Evidence for this has been primarily developed by stud- 
ies of cytomegalovirus (CMV) mfection, the single most important 
mfection in transplantation. Tumor necrosis factor, whether elab- 
orated in response to allograft rejection, antilymphocyte antibody 
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therapy, or in the course of other infections such as urosepsis, is the 
prime factor involved in reactivating CMV from latency, the first step 
in the pathogenesis of systemic infection. Host defense defects, in- 
duced by CMV, particularly impaired cell mediated immunity, alve- 
olar macrophage dysfunction, and neutropenia, are translated into an 
increased incidence of fungal (includmg Pneumocystis) and bacterial 
infection. Growth factors and cytokines released as a consequence 
of CMV infection upregulate the display of MHC antigens and the 
state of activation of leukocytes and vascular endothelium - the end 
result being luograft injury. There is thus a bidirectional relationship 
between CMV (and infection) and allognft injury. Finally, CMV 
infection is associated with a =- 7 fold increase in the incidence of 
post-transplant lymphoproliferative &ease. 
Resistant enterococci 
1 5129 1 Activity of Teicoplanin, Vancomycin and 8 Other 
DNgs against Gram-Positive Pathogens Isolated 
in Italy 
G.C. Schito, A. Pesce, A. Marchese, E.A. Debbia for the Italian 
Glycopeptide Resistance Group. Institute ofMhobiolo0, School .f 
Medicine, Univm'ty of Genoa, Italy 
At present only the glycopeptides teicoplanin and vancomycin re- 
rain, in most sites, a consistent activity against multi-drug resistant 
Gram-positive pathogens responsible for serious infections in the 
community and in nosocomial settings. Thus, monitoring their con- 
tinous efficacy becomes essential since the chcians are accustomed 
to use these drugs on an empirical basis. In 1995 a large multi- 
center s t u d y  enrolling 70 laboratories in 9 European countries has 
analysed 6824 Gram-positive isolates for susceptibility to the two 
glycopeptides. In Italy, besides teicoplanin and vancomycin, the in 
vim activity of several other relevant drugs was assessed by an agar 
dilution method (NCCLS) on the collection of strains (807) sent 
to this coordinating laboratory. Percent susceptible organisms at the 
breakpoints (NCCLS, 1995) are reported in the table for the antibi- 
otics tested: 
Pathogen N % Susceptible organisms to 
amp pen cef imi ncc ely nor cip tei van 
Suph. (MS) 280 32.5 100 100 95 51 75 69 100 100 
Suph. (MR) 219 80 10 14 10 99.6 100 
E . j d r  247 87 94 66 42 99.6 99.6 
E. fbrdum 46 28 43 52 17 100 9a 
This survey confirms that teicoplanin is more active than van- 
comycin on Enterococci and that it displays in practice comparable 
potency agamst the Staphylococci. In accordance with the data ob- 
tained in other countries it may be concluded that usage of the two 
glycopeptides, as occurring in Europe, may delay the appearance and 
spread of glycopeptide-resistant Gnm-positive pathogens as experi- 
enced in other regions of the world where only one molecule is 
employed. One possible mechanism for this may be ascribed to the 
fact that vancomycin can easily induce organisms carrying the V a d  
phenotype to full blown resistance while teicoplanin is devoid of this 
untoward effect. 
Glycopeptide Resistance in Enterococci: An Old 
New Resistance Mechanism 
P. Courvalin, M. Arthur, P. Reynolds. Institut Pasteur, Paris, France 
Glycopeptide resistance in enterococci is phenotypically and geno- 
typically heterogeneous. Inducible resistance to high levels of van- 
comycin and teicoplanin (VanA type) is mediated by self-transferable 
plasmids and the genes are carried by aansposon TnZ546and related 
elements. Nine polypeptides are encoded by TnZ546 that can be as- 
signed to five functional groups: transposition functions (ORFl and 
ORF2), regulation of resistance gene expression (VanR and Vans), 
synthesis of depsipeptide D-Ala-D-lactate (VanH and VanA), hydrol- 
ysis of D-Ah-D-Ah-containing peptidoglycan precursors (VanX and 
VanY) and low-level teicoplanin resistance (VanZ). The VanH de- 
hydmgenase and the VanA ligase synthesize D-Ala-D-lactate which 
replaces D-Ala-D-Ala in the peptidoglycan synthesis pathway. This 
moacation reduces the al€~mity of glycopeptides for peptidoglycan 
precursors. Strains with the VanB phenotype are inducibly resis- 
tant to various levels of vancomycin (MIC 4-1000 pg/ml), also by 
production of D-Ala-D-Lac. These strains remain susceptible to te- 
icoplanin although vancomycin induces resistance to this antibiotic. 
The compacmess and organization of the van gene clusters as well 
as the dual mechanism of resistance indicate that glycopeptide resis- 
tance is ancient. Analysis of the genes and gene order in the v a t 4  
and vanB operons and the study of the base composition within the 
clusters suggest that genes h m  merent origins have been recruited. 
Probiotic Products of Enterococci and 
Resistance 
E. Gutschik. University .f Copenhagen, Bispeljerg Hospital, Denmark 
Probiotics could be defined as non-pathogenic, host derived mi- 
croorganism which beneficially effects the host by improving micro- 
biological balance of the target niche (S.A.W Gibson). Enterocacrus 
facium (EfJ is a fast lactic acid producer and used for cheese fermen- 
tation, and fermentation of youghurt dvry products. Freeze-dried 
products of Ef has been on the market in many European countries 
as tablets or capsules with 108-109 CFU used to treat diarrhoeal 
diseases. Furthermore, same strains and preparations arevsed to treat 
diarrhoe in piglets and as dietary adjunct for newly hatched chicks 
and poults. There is a concern that vancomycin resistant enterococci 
(VRE) could emerge in human beings by simultaneous consump- 
tion of high number of enterococci and vancomycin or &om animal 
environment using probiotics of Ef. In Denmark a prodrug of Ef 
has been on the market since 1922, a yoghurt product of Ef mar- 
keted in almost all supermarkets throughout of the country, and a 
glycopeptid antibiotic; avoparcin has been used as food additive in 
animal farming for more than a decade (but banned in the spring 
of 1995). In spite of this, VRE strains almost never recognized in 
clinical specimens. Recent investigations of 65 dinically important 
isolates of enterococci (consisting 52 blood isolates) tested by PCR 
only recognized one van A positive st ra in  (MIC > 256 pg/ml) and 
one van B isolate (MIC 12 pg/ml). The global and the Scandina- 
vian experience reject any indication that the use of well-described 
and quality controlled prodrugs of Ef in humans play a signhcant 
roll for the increasing antibiotic resstance of enterococci. Theoreti- 
cally, the simultaneous use antibiotics and prodrugs of Ef as dietary 
supplementation in animals could result in selection of multiresistant 
enterococci. and should be banned. 
